{"id":"tp-40160","type":"article-newspaper","title":"BeOne Reports 36% Response Rate for Liver Cancer Drug in Phase 1","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/40160","datePublished":"2026-10-24T17:10:57.000Z","dateModified":"2026-10-24T17:10:57.000Z","language":"en","abstract":"The result came from 25 evaluable patients given 450 milligrams every three weeks; BeOne plans larger trials by the end of 2026.","section":"Business","references":[]}